Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 15 Best Boring Dividend Stocks to Buy, indicating its stable dividend profile despite limited growth [1] - The company is experiencing a lack of significant growth but remains profitable, with a payout ratio of approximately 84%, which is considered sustainable given its free cash flow of $15.3 billion over the past 12 months, significantly exceeding the $5 billion paid in dividends [3] - Concerns exist regarding the long-term sustainability of dividends due to the company's net debt of $32 billion, although this is a reduction from $38.5 billion at the beginning of the year [4] Group 2 - Positive Phase 3 trial results for Bayer's FXIa inhibitor asundexian have drawn attention to the FXIa drug class, potentially increasing interest in similar treatments from Bristol-Myers Squibb and Johnson & Johnson, although Morgan Stanley remains cautious on BMY despite initial stock gains [2]